Sartorius | 179.50 / 0.00% |
Date/Time | 12/09 / 22:00 |
Chg. / Chg.(%) | 0.00 / 0.00% |
Bid | 198.00 / 120 |
Ask | 202.40 / 120 |
Open | 179.50 |
Previous Close | 179.50 |
High | 179.50 |
Low | 179.50 |
Volume [CHF] | - |
Volume [Units] | |
Price fixings | 1 |
ISIN | DE0007165631 |
Security | SRT3 |
Exchange | SIX Swiss Exchange |
Type | Stock |
Other Exchanges
Exchange | Last | Volume | |
---|---|---|---|
Xetra | 193.10 | ![]() |
35,033 |
Cboe Europe .. | 192.60 | ![]() |
7,367 |
London Inter.. | 191.45 | ![]() |
5,443 |
Cboe Europe .. | 192.60 | ![]() |
4,134 |
Turquoise | 192.40 | ![]() |
3,395 |
TradeGate | 192.400 | ![]() |
2,372 |
Frankfurt | 193.8000 | ![]() |
821 |
Stuttgart | 192.800 | ![]() |
230 |
Berlin | 191.60 | ![]() |
40 |
gettex | 193.300 | ![]() |
20 |
Vienna Globa.. | 192.70 | ![]() |
0 |
München | 191.70 | ![]() |
0 |
Hamburg | 191.90 | ![]() |
0 |
Hannover | 191.90 | ![]() |
0 |
Düsseldorf | 191.90 | ![]() |
0 |
SIX Swiss Ex.. | 179.50 | ![]() |
|
Lang & Schwa.. | 192.700 | ![]() |
|
Nasdaq Other.. | 213.5000 | 120 | |
EUREX | Options |
News
- XBiotech Announces Rapid Enrollment for its Randomized Multi-Center Clinical Study for Bermekimab in Patients with Hidradenitis Suppurativa
11/19/2019 / 14:55 - GlobeNewswire - Worldwide Cell Based Assay & High Content Screening Market Forecasts to 2024 - Candidate Growth, Immuno-oncology, Genomic Blizzard, Technology Convergence, The Insurance Effect
10/29/2019 / 11:55 - GlobeNewswire - XBiotech Announces First Patient Enrolled in Randomized Multi-Center Clinical Study Evaluating Bermekimab Therapy in Patients with Hidradenitis Suppurativa
10/23/2019 / 14:15 - GlobeNewswire - Global $1.78Bn Fermenters Market Outlook, 2025
10/23/2019 / 11:26 - GlobeNewswire - 2019 Report on Cell Harvesting: Market Projected to Grow by $157.2M During 2019-2025
10/22/2019 / 18:05 - GlobeNewswire